JP2014500009A5 - - Google Patents

Download PDF

Info

Publication number
JP2014500009A5
JP2014500009A5 JP2013537771A JP2013537771A JP2014500009A5 JP 2014500009 A5 JP2014500009 A5 JP 2014500009A5 JP 2013537771 A JP2013537771 A JP 2013537771A JP 2013537771 A JP2013537771 A JP 2013537771A JP 2014500009 A5 JP2014500009 A5 JP 2014500009A5
Authority
JP
Japan
Prior art keywords
amino acid
antibody
seq
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537771A
Other languages
English (en)
Japanese (ja)
Other versions
JP6126532B2 (ja
JP2014500009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/058869 external-priority patent/WO2012061448A1/en
Publication of JP2014500009A publication Critical patent/JP2014500009A/ja
Publication of JP2014500009A5 publication Critical patent/JP2014500009A5/ja
Application granted granted Critical
Publication of JP6126532B2 publication Critical patent/JP6126532B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537771A 2010-11-04 2011-11-02 抗il−23抗体 Active JP6126532B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US41015810P 2010-11-04 2010-11-04
US61/410,158 2010-11-04
US41195310P 2010-11-10 2010-11-10
US61/411,953 2010-11-10
US41259410P 2010-11-11 2010-11-11
US61/412,594 2010-11-11
US201161448785P 2011-03-03 2011-03-03
US61/448,785 2011-03-03
PCT/US2011/058869 WO2012061448A1 (en) 2010-11-04 2011-11-02 Anti-il-23 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017003955A Division JP6445596B2 (ja) 2010-11-04 2017-01-13 抗il−23抗体

Publications (3)

Publication Number Publication Date
JP2014500009A JP2014500009A (ja) 2014-01-09
JP2014500009A5 true JP2014500009A5 (enExample) 2014-12-25
JP6126532B2 JP6126532B2 (ja) 2017-05-10

Family

ID=44936573

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013537771A Active JP6126532B2 (ja) 2010-11-04 2011-11-02 抗il−23抗体
JP2017003955A Active JP6445596B2 (ja) 2010-11-04 2017-01-13 抗il−23抗体
JP2018223469A Active JP6758361B2 (ja) 2010-11-04 2018-11-29 抗il−23抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017003955A Active JP6445596B2 (ja) 2010-11-04 2017-01-13 抗il−23抗体
JP2018223469A Active JP6758361B2 (ja) 2010-11-04 2018-11-29 抗il−23抗体

Country Status (39)

Country Link
US (6) US8778346B2 (enExample)
EP (4) EP3456740A1 (enExample)
JP (3) JP6126532B2 (enExample)
KR (2) KR102049223B1 (enExample)
CN (2) CN107522784B (enExample)
AP (1) AP3953A (enExample)
AR (1) AR083747A1 (enExample)
AU (3) AU2011323426B2 (enExample)
BR (1) BR112013011065B1 (enExample)
CA (2) CA2816950C (enExample)
CO (1) CO6801628A2 (enExample)
CY (2) CY1118014T1 (enExample)
DK (1) DK2635601T3 (enExample)
EA (2) EA201890548A1 (enExample)
EC (1) ECSP13012649A (enExample)
ES (1) ES2593754T3 (enExample)
GE (1) GEP201706733B (enExample)
HR (1) HRP20161141T1 (enExample)
HU (2) HUE030916T2 (enExample)
IL (2) IL225648A (enExample)
LT (2) LT2635601T (enExample)
LU (1) LUC00132I2 (enExample)
MA (1) MA34641B1 (enExample)
ME (1) ME02499B (enExample)
MX (3) MX2019000046A (enExample)
MY (1) MY162791A (enExample)
NL (1) NL301013I2 (enExample)
NO (1) NO2019038I1 (enExample)
NZ (1) NZ610592A (enExample)
PE (1) PE20141162A1 (enExample)
PH (1) PH12013500810B1 (enExample)
PL (1) PL2635601T3 (enExample)
PT (1) PT2635601T (enExample)
RS (1) RS55161B1 (enExample)
SG (2) SG190006A1 (enExample)
SI (1) SI2635601T1 (enExample)
TW (2) TWI653242B (enExample)
UY (1) UY33703A (enExample)
WO (1) WO2012061448A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SG190006A1 (en) * 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
NZ700802A (en) 2012-05-03 2017-06-30 Boehringer Ingelheim Int Anti-il-23p19 antibodies
AR094877A1 (es) * 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
EP3689369A1 (en) 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
WO2014143540A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
IL321788A (en) * 2015-02-04 2025-08-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
EP3391905A1 (en) * 2015-04-14 2018-10-24 Boehringer Ingelheim International GmbH Treatment of asthma with anti-il-23a antibodies
AU2016297575B2 (en) * 2015-07-23 2021-05-27 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
RU2018113694A (ru) * 2015-09-17 2019-10-17 Эмджен Инк. Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
SMT202200118T1 (it) * 2015-11-03 2022-05-12 Janssen Biotech Inc Anticorpi che legano specificamente pd-1 e loro usi
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
US20170298126A1 (en) 2016-04-15 2017-10-19 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
EP3848390A1 (en) 2016-10-14 2021-07-14 Boehringer Ingelheim International GmbH Methods of treating diseases
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3090479A1 (en) * 2018-02-05 2019-08-08 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods
TWI744617B (zh) 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
CN112689643A (zh) 2018-07-13 2021-04-20 阿斯特捷利康合作创业有限责任公司 用布雷库单抗治疗溃疡性结肠炎
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN109810947B (zh) * 2019-01-18 2021-06-11 北京贝来生物科技有限公司 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用
MX2021012652A (es) * 2019-04-15 2022-01-24 Sun Pharmaceutical Ind Ltd Metodos para el tratamiento de sujetos con artritis psoriasica.
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
CA3164996A1 (en) 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
CN111956606B (zh) * 2020-08-31 2021-05-14 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂
TWI904235B (zh) 2020-09-10 2025-11-11 美商美國禮來大藥廠 治療性抗體調配物
AR123767A1 (es) 2020-10-13 2023-01-11 Janssen Biotech Inc Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii
US20240254217A1 (en) 2021-05-28 2024-08-01 Eli Lilly And Company Anti -il-23p19 antibody regulation of genes involved in ulcerative colitis
KR102761841B1 (ko) 2021-07-09 2025-02-05 연세대학교 산학협력단 Il-23에 의해 매개되는 질환의 중증도 예측용 조성물
EP4409298A1 (en) 2021-09-30 2024-08-07 Eli Lilly and Company Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis
WO2024085697A1 (en) 2022-10-21 2024-04-25 Chong Kun Dang Pharmaceutical Corp. Stable antibody composition
KR20250152080A (ko) 2023-02-22 2025-10-22 일라이 릴리 앤드 캄파니 궤양성 결장염에서의 유전자의 조절 및 그의 용도
AU2024312669A1 (en) * 2023-06-22 2026-02-05 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
US20250228864A1 (en) 2023-11-29 2025-07-17 Gilead Sciences, Inc. Therapies for the treatment of inflammatory bowel disease
TW202540171A (zh) 2024-02-06 2025-10-16 美商派拉岡醫療公司 Il-23抗體組合物及使用方法
TW202540172A (zh) * 2024-02-06 2025-10-16 美商派拉岡醫療公司 Il-23結合蛋白組合物及使用方法
CN117875575B (zh) * 2024-03-12 2024-05-28 中国电子科技集团公司第二十九研究所 一种基于混合仿生算法的干扰资源分配方法

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DK0656789T3 (da) 1992-08-21 1998-08-24 Genentech Inc Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse.
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CO4810232A1 (es) 1997-07-25 1999-06-30 Schering Corp Citoquinas de mamiferos y sus secuencias codificadoras
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
AU2661199A (en) 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods
DE69942607D1 (de) 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
HK1044170B (en) 1999-09-09 2008-08-01 Merck Sharp & Dohme Corp. Mammalian interleukin-12 p40 and interleukin b30. combinations thereof. antibodies. uses in pharmaceutical compositions
CZ304022B6 (cs) 2000-05-10 2013-08-28 Merck Sharp & Dohme Corp. Savcí receptorové proteiny, cinidla a metody, které se jich týkají
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20050039222A1 (en) 2001-10-24 2005-02-17 Kiyoshi Habu Sgrf gene-modified non-human animals
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
EP2108660A1 (en) 2002-10-30 2009-10-14 Genentech, Inc. Inhibition of IL-17 production
JP4902961B2 (ja) 2002-12-23 2012-03-21 シェーリング コーポレイション 哺乳動物サイトカインの用途;関連試薬
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
SI1601694T1 (sl) 2003-03-10 2010-01-29 Schering Corp Uporabe IL-23 antagonistov; sorodni reagenti
WO2005005612A2 (en) 2003-07-01 2005-01-20 University Of Virginia Patent Foundation Tag-1 and tag-2 proteins and uses thereof
DK1684805T3 (da) 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
SG148143A1 (en) 2003-11-04 2008-12-31 Novartis Vaccines & Diagnostic Antagonist anti-cd40 monoclonal antibodies and methods for their use
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
AU2005215527B2 (en) 2004-02-17 2011-04-07 Merck Sharp & Dohme Corp. Methods of modulating IL-23 activity; related reagents
WO2005108616A1 (en) 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
CA2581505A1 (en) * 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2292758A3 (en) 2004-12-20 2013-12-25 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents
PT2452694T (pt) * 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
AU2006265898A1 (en) 2005-06-30 2007-01-11 Archemix Corp. Polynucleotides and polypeptides of the IL-12 family of cytokines
CN101248088A (zh) * 2005-08-25 2008-08-20 伊莱利利公司 抗il-23抗体
AU2006283194B9 (en) * 2005-08-25 2011-02-03 Eli Lilly And Company Anti-IL-23 Antibodies
LT1931710T (lt) * 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
EP2322219A3 (en) 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
WO2007076523A2 (en) 2005-12-28 2007-07-05 Centocor, Inc. Markers and methods for assessing and treating psoriasis and related disorders
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
MX2008015446A (es) 2006-06-19 2008-12-12 Wyeth Corp Metodos de modulacion il-22 e il-17.
EP2114451A2 (en) 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
EP2124889A2 (en) 2007-02-16 2009-12-02 Wyeth a Corporation of the State of Delaware Protein formulations containing sorbitol
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
CN101668531B (zh) 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
CA2698357C (en) 2007-09-04 2017-06-06 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
CA2703333A1 (en) 2007-10-26 2009-04-30 Galderma Research & Development Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof
CA2607771A1 (en) 2007-11-01 2009-05-01 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Humanized anti-venezuelan equine encephalitis virus recombinant antibody
NZ622583A (en) 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
AR073060A1 (es) 2008-08-14 2010-10-13 Arana Therapeutic Ltd Anticuerpos anti-il-12/il-23
CN102202655B (zh) 2008-08-27 2013-06-19 默沙东公司 基因工程抗IL-23p19抗体的冻干制剂
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
WO2010115092A2 (en) 2009-04-02 2010-10-07 The Johns Hopkins University Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN102740888B (zh) 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
CN102695465A (zh) 2009-12-02 2012-09-26 斯帕泰克医疗股份有限公司 结合具有可偏转柱和复合脊柱杆的骨锚固件的小轮廓脊柱假体
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
BR112012019881A2 (pt) 2010-02-18 2017-06-27 Bristol Myers Squibb Co proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
BR112012022223B1 (pt) 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
JP2013531499A (ja) 2010-06-15 2013-08-08 セルジーン コーポレイション 乾癬の治療のためのバイオマーカー
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
CA2805653A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
WO2012032181A2 (en) 2010-09-10 2012-03-15 Allozyne, Inc Novel antibody derivatives
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
TW201309330A (zh) 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途
US9078894B2 (en) 2011-02-04 2015-07-14 Ab Science Treatment of severe persistant asthma with masitinib
NZ700802A (en) 2012-05-03 2017-06-30 Boehringer Ingelheim Int Anti-il-23p19 antibodies
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
EP3689369A1 (en) 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
WO2014143540A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
IL321788A (en) 2015-02-04 2025-08-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
AU2016297575B2 (en) 2015-07-23 2021-05-27 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法

Similar Documents

Publication Publication Date Title
JP2014500009A5 (enExample)
RU2474588C2 (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
JP2012531922A5 (ja) Toll様受容体2へのヒト化抗体またはその抗原結合部位
JP2017502695A5 (enExample)
JP2010526028A5 (enExample)
HRP20161141T1 (hr) Anti-il-23 protutijela
JP2019522961A5 (enExample)
CN109311974A (zh) 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
JP2020532965A5 (enExample)
JP2011207882A5 (enExample)
JP2014526898A5 (enExample)
JP2011514150A5 (enExample)
JP2013538553A5 (enExample)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2012524071A5 (enExample)
JP2012100667A5 (enExample)
JP2010534478A5 (enExample)
RU2011149334A (ru) Анти-il-17f антитела и способы их применения
HRP20130204T1 (hr) Monoklonalna protutijela koja se vežu na hgm-csf i medicinski sastavi koji ih sadrže
JP2017512838A5 (enExample)
RU2013110874A (ru) Антитела против il-18r1 и их применения
JP2015504306A5 (enExample)
JP2016520595A5 (enExample)
JP2015511931A5 (enExample)
JP2020511946A5 (enExample)